<DOC>
	<DOCNO>NCT01719835</DOCNO>
	<brief_summary>This randomise , open-label phase II study compare GEM-P chemotherapy ( experimental arm ) CHOP ( control arm ) previously untreated T-cell lymphoma . Eligible patient randomise 1:1 4-weekly GEM-P 3-weekly CHOP chemotherapy .</brief_summary>
	<brief_title>CHOP vs GEM-P 1st Line Treatment T-cell Lymphoma , Multicentre Phase II Study</brief_title>
	<detailed_description>Background : T-cell lymphoma aggressive rare subset Non-Hodgkin lymphoma ( NHL ) comprise several different subtypes disease within group . No standard first-line treatment exist T-cell lymphoma publish series small , heterogeneous population often retrospective . PROTOCOL SYNOPSIS Study Period : 5 year Objectives : Primary • To compare complete response rate GEM-P CHOP chemotherapy first line treatment patient T - cell Lymphoma . Secondary To investigate , arm : - Rate metabolic complete response - Toxicity treatment - Overall survival ( OS ) - Progression Free Survival ( PFS ) Exploratory - Investigate impact International Prognostic Index ( IPI ) outcomes response rate , PFS OS Study Design : A randomised multi-centre open-label phase II study Indication : Previously untreated T-Cell lymphoma No Participants : 186 ( 93 patient arm ) Main Eligibility Criteria - Histologically proven T-cell lymphoma follow subtypes : - Peripheral T-cell lymphoma NOS - Systemic Anaplastic large cell lymphoma ( ALCL ) Anaplastic lymphoma kinase ( ALK ) negative case - Angioimmunoblastic T-cell lymphoma - Hepatosplenic gamma/ delta T-cell lymphoma - Bulky Stage I , Stage II , III IV - No prior chemotherapy regimen - Patients age 18 year . - WHO performance status 0,1 2 - Adequate organ function : - No Central Nervous System ( CNS ) leptomeningeal involvement lymphoma - No treatment lymphoma within 4 week commence trial therapy - No known HIV , Hepatitis C active Hepatitis B viral infection Treatment : CHOP : cyclophosphamide , doxorubicin , vincristine , prednisolone every 21 day . GEM-P : gemcitabine , methylprednisolone , cisplatin every 28 day . Assessment Schedule : - Patients review baseline prior schedule dose treatment toxicity - Radiological tumour assessment do CT scan every 2 cycle Arm A cycle 1 , 3 4 Arm B - PET/CT scan perform baseline upon completion treatment.. - Follow completion treatment 3 , 6 , 9 , 12 , 18 , 24 month annually 5 year total . CT scan perform 3 &amp; 12 month . - Following disease progression patient follow survival every 3 month death</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Previously untreated , histologically proven Tcell Lymphoma ( follow ) : Peripheral Tcell lymphoma Not Otherwise Specified ( PTCL NOS ) Systemic Anaplastic large cell lymphoma ( ALCL ) ALK negative case Angioimmunoblastic Tcell lymphoma Hepatosplenic gamma/ delta Tcell lymphoma Bulky stage I consider reduced chemotherapy plus involved field radiotherapy stage II , III IV . Patient male female , ≥18 year age day sign informed consent . WHO performance status 0 , 1 2 . Cross sectional imaging baseline contrast enhance CT show least one measurable disease site least 2 cm long diameter measurable two perpendicular dimension without correspond Fluorodeoxyglucose ( FDG ) avid lesion . Adequate cardiac function ; formal assessment leave ventricular ejection fraction require clinically indicate ( baseline echocardiogram do patient either hypertension , age &gt; 60 year history cardiac disease ) Adequate bone marrow function : absolute neutrophil count ( ANC ) ≥1.0x109/l ; white blood cell count ≥ 3x109/l ; platelet ≥ 100x109/l ; haemoglobin ( Hb ) ≥ 9g/dl ( posttransfusion ) , unless deem disease related Adequate renal function : calculated creatinine clearance ≥50ml/minute . Adequate liver function : serum bilirubin ≤1.5x Upper limit normal ( ULN ) ; Alanine transaminase/Aspartate transaminase ( ALT/AST ) ≤2.5x ULN ; ALP ≤3x ULN ( absence liver metastasis ) . If liver metastasis present , ALT , AST Alkaline phosphatase ( ALP ) ≤5x ULN permit . Isolated hyperbilirubinaemia due Gilbert 's disease acceptable Female patient childbearing potential must negative serum urine βhuman chorionic gonadotropin ( hCG ) pregnancy test baseline . Written informed consent must obtain prior start study treatment . Scans bone marrow biopsy perform within 4 week commencement therapy acceptable provide perform accord study requirement . Patient agreeable use contraception period study treatment 12 month last dose study drug . Documented symptomatic central nervous system involvement leptomeningeal disease . Patients measurable disease contrast enhance CT scan baseline . Any clinically significant disease comorbidity may adversely affect safe delivery treatment within trial . Any malignancy diagnose treat within last 5 year ( curatively treat basal cell carcinoma skin and/or situ carcinoma cervix ) . Treatment another investigational agent within 30 day commence study treatment . Known positive test human immunodeficiency virus ( HIV ) infection , hepatitis C virus , acute active hepatitis B infection . Patient pregnant breastfeeding , expect conceive father child within one year finishing study treatment . Patients poorly control diabetes mellitus Hypersensitivity contraindication study drug state Summaries product characteristic ( SmPCs ) study drug . Patients previous cardiac infarct satisfactory cardiac function may allow discretion Chief Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>T cell lymphoma</keyword>
	<keyword>untreated</keyword>
</DOC>